Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial

Summary

Trial Summary
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:

Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: